SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint...Read more
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161 LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the...Read more
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data...Read more
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many...Read more
Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN, April 26, 2024 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the...Read more
Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive FOSTER CITY,...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| ResMed | 34.64 18.89 | $218.06 |
| IDEXX Laboratories | 10.06 2.06 | $499.30 |
| Eli Lilly | 8.64 1.19 | $733.51 |
| ICON | 8.23 2.74 | $308.31 |
| ZIVO Bioscience | 7.00 636.36 | $8.10 |
| Biogen | 6.44 3.18 | $208.90 |
| Inspire Medical Systems | 6.44 2.79 | $237.45 |
| Medpace | 6.16 1.58 | $395.93 |
| Avenue Therapeutics | 6.07 5,190.60 | $6.19 |
| Cullinan Oncology | 6.05 31.43 | $25.30 |
| Viking Therapeutics | 5.45 7.91 | $74.31 |
| Mettler-Toledo | 5.18 0.42 | $1,238.09 |
| Zoetis | 5.06 3.30 | $158.42 |
| BeiGene | 5.02 3.38 | $153.58 |
| Annovis Bio | 4.41 32.43 | $18.01 |
| Korro Bio | 4.40 7.52 | $62.93 |
| ZyVersa Therapeutics | 4.38 721.40 | $4.99 |
| argenx | 4.20 1.14 | $372.80 |
| Company | Volume | Last Trade |
|---|---|---|
| Ginkgo Bioworks | 71,157,495 | $0.86 |
| Biodexa Pharmaceuticals | 70,092,348 | $1.30 |
| Kintara Therapeutics | 50,979,698 | $0.15 |
| Jaguar Health | 42,904,521 | $0.18 |
| Therapeutic Solutions | 41,537,543 | $0.0006 |
| ImmunityBio | 39,079,607 | $7.35 |
| Pfizer | 36,698,447 | $25.40 |
| Sunshine Biopharma | 31,809,747 | $0.95 |
| Bristol-Myers Squibb | 19,714,694 | $44.85 |
| Nuwellis | 18,260,885 | $0.17 |
| Gilead Sciences | 12,348,617 | $65.42 |
| X4 Pharmaceuticals | 10,837,407 | $1.17 |
| AbbVie | 10,358,332 | $159.62 |
| Teva Pharmaceutical | 10,128,795 | $13.81 |
| Boston Scientific | 8,646,023 | $73.17 |
| DexCom | 8,547,988 | $124.34 |
| PacBio | 7,916,917 | $1.47 |
| Geron | 7,823,390 | $3.79 |
| Teladoc Health | 7,596,555 | $13.01 |
| Merck | 7,414,284 | $131.20 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is installed...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
